Want to see HK:1312 full AI Analyst Report?
Top Page
Kontafarma China Holdings Ltd
(1312)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.03
▲(10.00% Upside)
Action:Reiterated
Date:08/20/26
The score is held back primarily by weak profitability and sharply widening net losses despite strong gross margins, which also pressured equity and returns. Offsetting this, cash flow has improved and leverage has declined, reducing balance-sheet risk. Technically the stock shows mild positive momentum, while valuation is hard to judge given negative earnings and no dividend yield data.
Positive Factors
Strong gross margins
Sustained gross margins near 49%–58% indicate favorable product economics, pricing capability, or mix. This provides a foundation for future profitability if the company can control operating costs and convert gross profit into positive EBIT.
Negative Factors
Persistent operating losses
Negative EBIT and EBITDA show that strong gross margins are not covering operating expenses, charges, or other costs. The sharply wider 2025 net loss indicates weak operating leverage and leaves profitability dependent on a substantial cost or business-model improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong gross margins
Sustained gross margins near 49%–58% indicate favorable product economics, pricing capability, or mix. This provides a foundation for future profitability if the company can control operating costs and convert gross profit into positive EBIT.
Read all positive factors
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$189.68M
Dividend Yield2.96%
Average Volume (3M)1.62M
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth-5.20%
EPS Growth41.38%
CountryHK
Employees636
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding5,588,572,000
10 Day Avg. Volume2,196,000
30 Day Avg. Volume1,624,200
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Company Description
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory...
How the Company Makes Money
null...
Kontafarma China Holdings Ltd Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
46
Neutral
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 845.33M | 914.71M | 897.52M | 809.11M | 894.06M | 803.27M |
| Gross Profit | 437.76M | 513.64M | 516.16M | 471.29M | 506.22M | 396.18M |
| EBITDA | -17.10M | -153.53M | -49.93M | 78.50M | 26.93M | 112.18M |
| Net Income | -212.80M | -427.85M | -75.54M | -28.84M | -41.55M | -15.05M |
Balance Sheet | ||||||
| Total Assets | 997.37M | 1.07B | 1.59B | 1.73B | 2.12B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 67.62M | 66.06M | 90.58M | 87.66M | 142.59M | 183.96M |
| Total Debt | 189.76M | 203.68M | 297.19M | 333.82M | 590.72M | 728.95M |
| Total Liabilities | 579.08M | 588.92M | 625.90M | 665.39M | 964.16M | 1.22B |
| Stockholders Equity | 510.20M | 553.26M | 978.70M | 1.06B | 1.10B | 1.19B |
Cash Flow | ||||||
| Free Cash Flow | 9.57M | 53.15M | 33.41M | 12.92M | -53.84M | -49.31M |
| Operating Cash Flow | 29.21M | 76.68M | 47.05M | 37.12M | -2.17M | 75.07M |
| Investing Cash Flow | 6.65M | 8.82M | -6.01M | 144.14M | 121.53M | 23.24M |
| Financing Cash Flow | -56.89M | -90.16M | -42.52M | -198.81M | -137.33M | -99.80M |
Kontafarma China Holdings Ltd Technical Analysis
Negative
0.03
Price Trends
0.03
Negative
0.03
Positive
0.03
Positive
Market Momentum
<0.01
Positive
48.24
Neutral
2.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 2.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1312.
Kontafarma China Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$40.25B | 11.77 | 7.71% | 4.13% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$739.99M | 2.16 | 1.79% | 2.05% | ― | ― | |
49 Neutral | HK$189.68M | -0.86 | -40.02% | 2.96% | -5.20% | 41.38% | |
45 Neutral | HK$55.56M | -0.90 | -18.70% | 4.32% | 43.00% | -74.41% | |
44 Neutral | HK$26.27B | -2.67 | -5.48% | 4.99% | 0.12% | -214.59% | |
42 Neutral | HK$522.11M | -0.10 | 99.19% | 2.20% | ― | ― |
* Healthcare Sector Average
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
22.22%
HK:3323
China National Building Material Co
3.43
-2.09
-37.83%
HK:0868
Xinyi Glass Holdings
8.83
0.38
4.45%
HK:3300
China Glass Holdings Limited
0.31
0.04
14.81%
HK:1252
China Tianrui Group Cement Co., Ltd.
0.24
-0.13
-35.14%
HK:1847
YCIH Green High-Performance Concrete Co., Ltd. Class H
0.42
-0.27
-38.97%
Kontafarma China Holdings Ltd Corporate Events
Kontafarma Reshapes Top Management With New President and Executive Director
Aug 17, 2026
Kontafarma China Holdings Ltd has announced an internal reshuffle in its senior management, with chairman and executive director Wang Limin stepping down as president of the group while retaining his board roles and chairmanship of key governance ...
Kontafarma China Refines Board and Committee Structure for Stronger Governance
Aug 17, 2026
Kontafarma China Holdings Ltd has updated its board composition effective 17 August 2026, confirming a seven-member Board comprising four executive directors and three independent non-executive directors. Wang Limin serves as chairman, supported b...
Kontafarma China Delays Circular on Major Fitness Centre Lease Renewal
Aug 17, 2026
Kontafarma China Holdings Limited has postponed the despatch of a shareholder circular relating to the renewal of a lease for an existing fitness and yoga centre, classified as a major transaction under Hong Kong listing rules. The circular, origi...
Kontafarma China Sets August Board Meeting to Review Interim Results and Dividend
Aug 17, 2026
Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, is guided by a seven-member board featuring four executive directors and three independent non-executive directors. The team is led by Chairman Wang Lim...
Kontafarma Flags Smaller First-Half Loss Amid Fresh Singapore Fitness Impairments
Aug 17, 2026
Kontafarma China Holdings has warned that it expects to post a consolidated net loss of between HK$67.2 million and HK$100.7 million for the six months ended 30 June 2026, a substantial improvement from the HK$321.4 million loss a year earlier. Th...
Kontafarma China Renews Major Lease for Fitness and Yoga Centre
Jul 27, 2026
Kontafarma China Holdings Ltd, through its indirect non-wholly owned subsidiary True Yoga Pte. Ltd., operates a fitness and yoga centre in leased premises. The group’s business model relies on securing and renewing long-term leases to mainta...
Kontafarma China Announces Resignation of Non-Executive Director Huang Yu
Jun 30, 2026
Kontafarma China Holdings Ltd announced that non-executive director Huang Yu will resign from the board effective 30 June 2026 to pursue personal career development, with both the company and Huang emphasizing there is no disagreement or outstandi...
Kontafarma China Refreshes Board and Committee Structure
Jun 30, 2026
Kontafarma China Holdings Limited has announced the latest composition of its board of directors, effective 30 June 2026, confirming Wang Limin as chairman and president alongside executives Ge Shouwen and Guo Zixiu. Independent non-executive dire...
Kontafarma China Wins Strong Shareholder Backing at 2026 AGM
Jun 5, 2026
Kontafarma China Holdings Ltd reported that all resolutions put to shareholders at its 5 June 2026 annual general meeting were approved by wide margins, with about 95.85% of votes cast in favour. Shareholders endorsed the 2025 audited financial st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.